Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs abrdn Physical Palladium Shares ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while abrdn Physical Palladium Shares ETF trades at $22.99. Which is the better fit depends on your goals.
| ALNY | PALL | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $491.22 | $37.18 |
52-Week Low | $278.09 | $19.96 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
PALL (abrdn Physical Palladium Shares ETF) trades at $23.07, up 1.63% with bearish technical signals from moving averages but neutral oscillators. The ETF recently underwent a 5-for-1 stock split effective May 18, 2026. Financial ratios are unavailable, but palladium's 47% price decline from January 2026 highs has drawn attention as a potential catch-up trade amid broader precious metals strength.
The outlook hinges on palladium's supply-demand dynamics, with Seeking Alpha highlighting a buying opportunity at current levels due to industrial demand and supply risks. Key risks include Federal Reserve policy impacts and commodity volatility. Analyst sentiment is cautiously optimistic, viewing the price weakness as a potential entry point for exposure to palladium's recovery prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
